Back

Navigating the realms of SGLT2 inhibitors bridging clinical studies enthusiasm with practical realities

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy 1 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mohamed ElRefai

Basildon University Hospital, Basildon (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Decline in functional capacity is associated with reduced ability to perform activities of daily living in patients with transthyretin cardiac amyloidosis: post hoc analysis of the APOLLO-B study
Doctor O. Lairez (Toulouse, FR)
Abstract Slides Video
Presentation thumbnail
Dapaglifozin in advanced heart failure patients : effects on congestion, NTproBNP and cardiorenal outcome
Doctor G. Ruocco (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Heart rate management practices across the spectrum of HFrEF patient journey in Indian clinical settings
Doctor V. Kolapkar (Thane, IN)
Abstract Slides Video
Presentation thumbnail
Age-related implications in guideline-directed medical therapy up-titration for heart failure with reduced ejection fraction
Doctor J. Cravo (Lisbon, PT) Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Home intravenous diuretics: a way to reduce hospital bed usage and urgent admissions
Doctor M. Castro (Guimaraes, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy 1

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies
thumbnail
Congress Presentation
Dapaglifozin in advanced heart failure patients : effects on congestion, NTproBNP and cardiorenal outcome
thumbnail
Congress Presentation
Real-world use of empaglifozin and dapaglifozin in patients with HEART failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources